BioCentury | Sep 9, 2020
Product Development

Sept. 8 Quick Takes: Phase III wins for Albireo, Merck and Spero; plus Corbus, Blueprint, AnHeart, Grifols-Alkahest, and Exelixis-NBE

...By BC Staff Albireo gains on Phase III...
...gains on Phase III rare liver diseases readout Albireo...
BioCentury | Aug 19, 2020
Finance

Aug. 18 Quick Takes: Chinook fuels up for NASDAQ liftoff; plus Kymera, Poseida, Albireo

...MAS), which has been associated with CAR Ts (see “Poseida Prices $224M IPO”).Albireo dropping elobixibat in NASH Albireo...
...acid transporter member 2 BC Staff P-PSMA-101 Goofice (Brand), AJG533 (Compound #), A3309 (Compound #), elobixibat (Generic) Poseida Therapeutics Inc. Albireo...
BioCentury | Mar 22, 2019
Company News

Management tracks: Mirum, Novocure

...external innovation at the EMD Serono unit of Merck KGaA (Xetra:MRK). Pediatric liver disease company Albireo...
...She was VP of global market access and value at Vertex Pharmaceuticals Inc. (NASDAQ:VRTX). BioCentury Staff Agenus Inc. Albireo...
BioCentury | Jan 5, 2019
Finance

Ready to launch

The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record year...
BioCentury | Jan 3, 2019
Company News

Management tracks: Barrett joins UroGen

...Cambridge, Mass.) hired Thomas Shea as CFO, a newly created position. He was CFO of Albireo...
BioCentury | Oct 10, 2018
Company News

Management tracks: Hamburg joins Alnylam board

...created position. Soffer was EVP and CSO of Atara Biotherapeutics Inc. (NASDAQ:ATRA). Liver disease company Albireo...
BioCentury | Jul 25, 2018
Company News

Management Tracks: Albireo, ObsEva

...Pediatric liver disease company Albireo Pharma Inc. (NASDAQ:ALBO) said CMO Paresh Soni will step down. He...
BioCentury | Jun 18, 2018
Company News

Management tracks: Ionis, Albireo

...CBO. He was SVP of corporate development at Acadia Pharmaceuticals Inc. (NASDAQ:ACAD). Hepatic disease company Albireo...
BioCentury | Apr 6, 2018
Finance

Fundamentally driven

...Source: Reuters Table: 1Q approvals1Q setbacks Selected 1Q approvals. Selected 1Q regulatory setbacks. Company Approval Albireo...
BioCentury | Jan 26, 2018
Financial News

GI and hepatic company Albireo raises $65M follow-on

...On Jan. 25, gastrointestinal and hepatic company Albireo Pharma Inc. (NASDAQ:ALBO) raised $65 million after selling...
...24, when it proposed the offering after hours. Albireo Pharma Inc. (NASDAQ:ALBO), Boston, Mass. Jaime De Leon Albireo...
Items per page:
1 - 10 of 57
BioCentury | Sep 9, 2020
Product Development

Sept. 8 Quick Takes: Phase III wins for Albireo, Merck and Spero; plus Corbus, Blueprint, AnHeart, Grifols-Alkahest, and Exelixis-NBE

...By BC Staff Albireo gains on Phase III...
...gains on Phase III rare liver diseases readout Albireo...
BioCentury | Aug 19, 2020
Finance

Aug. 18 Quick Takes: Chinook fuels up for NASDAQ liftoff; plus Kymera, Poseida, Albireo

...MAS), which has been associated with CAR Ts (see “Poseida Prices $224M IPO”).Albireo dropping elobixibat in NASH Albireo...
...acid transporter member 2 BC Staff P-PSMA-101 Goofice (Brand), AJG533 (Compound #), A3309 (Compound #), elobixibat (Generic) Poseida Therapeutics Inc. Albireo...
BioCentury | Mar 22, 2019
Company News

Management tracks: Mirum, Novocure

...external innovation at the EMD Serono unit of Merck KGaA (Xetra:MRK). Pediatric liver disease company Albireo...
...She was VP of global market access and value at Vertex Pharmaceuticals Inc. (NASDAQ:VRTX). BioCentury Staff Agenus Inc. Albireo...
BioCentury | Jan 5, 2019
Finance

Ready to launch

The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record year...
BioCentury | Jan 3, 2019
Company News

Management tracks: Barrett joins UroGen

...Cambridge, Mass.) hired Thomas Shea as CFO, a newly created position. He was CFO of Albireo...
BioCentury | Oct 10, 2018
Company News

Management tracks: Hamburg joins Alnylam board

...created position. Soffer was EVP and CSO of Atara Biotherapeutics Inc. (NASDAQ:ATRA). Liver disease company Albireo...
BioCentury | Jul 25, 2018
Company News

Management Tracks: Albireo, ObsEva

...Pediatric liver disease company Albireo Pharma Inc. (NASDAQ:ALBO) said CMO Paresh Soni will step down. He...
BioCentury | Jun 18, 2018
Company News

Management tracks: Ionis, Albireo

...CBO. He was SVP of corporate development at Acadia Pharmaceuticals Inc. (NASDAQ:ACAD). Hepatic disease company Albireo...
BioCentury | Apr 6, 2018
Finance

Fundamentally driven

...Source: Reuters Table: 1Q approvals1Q setbacks Selected 1Q approvals. Selected 1Q regulatory setbacks. Company Approval Albireo...
BioCentury | Jan 26, 2018
Financial News

GI and hepatic company Albireo raises $65M follow-on

...On Jan. 25, gastrointestinal and hepatic company Albireo Pharma Inc. (NASDAQ:ALBO) raised $65 million after selling...
...24, when it proposed the offering after hours. Albireo Pharma Inc. (NASDAQ:ALBO), Boston, Mass. Jaime De Leon Albireo...
Items per page:
1 - 10 of 57